Quantbot Technologies LP Purchases Shares of 25,813 Omnicell, Inc. $OMCL

Quantbot Technologies LP acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 25,813 shares of the company’s stock, valued at approximately $786,000. Quantbot Technologies LP owned about 0.06% of Omnicell as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Lazard Asset Management LLC grew its position in Omnicell by 3.8% during the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after acquiring an additional 62,733 shares during the period. Geode Capital Management LLC raised its holdings in shares of Omnicell by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock worth $35,163,000 after purchasing an additional 30,678 shares during the period. Qube Research & Technologies Ltd lifted its stake in shares of Omnicell by 38.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 653,971 shares of the company’s stock valued at $19,227,000 after purchasing an additional 181,394 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Omnicell by 1.7% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 461,506 shares of the company’s stock worth $13,568,000 after purchasing an additional 7,518 shares during the period. Finally, Liontrust Investment Partners LLP grew its holdings in shares of Omnicell by 81.2% during the 2nd quarter. Liontrust Investment Partners LLP now owns 318,284 shares of the company’s stock worth $9,358,000 after purchasing an additional 142,629 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the sale, the executive vice president owned 91,674 shares of the company’s stock, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on OMCL shares. Wells Fargo & Company raised their price target on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Benchmark boosted their price objective on shares of Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price on the stock in a research note on Wednesday, January 7th. Zacks Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $49.00 price target (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $54.50.

Omnicell Stock Performance

Omnicell stock opened at $41.30 on Friday. The firm has a market capitalization of $1.88 billion, a PE ratio of 1,032.76, a price-to-earnings-growth ratio of 1.48 and a beta of 0.79. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.00. The stock’s 50 day moving average price is $44.60 and its 200 day moving average price is $38.31. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. During the same period last year, the business earned $0.60 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. As a group, sell-side analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.